[Federal Register Volume 62, Number 99 (Thursday, May 22, 1997)]
[Notices]
[Pages 28032-28037]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-13429]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention
[Announcement 745]


Cooperative Agreement for Population-Based Surveillance of Fetal 
Alcohol Syndrome; Notice of Availability of Funds for Fiscal Year 1997

Introduction

    The Centers for Disease Control and Prevention (CDC) announces the 
availability of fiscal year (FY) 1997 funds for a cooperative agreement 
program to establish or enhance statewide, population-based 
surveillance of fetal alcohol syndrome (FAS). Population-based 
surveillance of FAS is important to document the magnitude of the 
problem and to monitor trends in the occurrence of this preventable 
birth defect. Ongoing surveillance is also essential in documenting the 
impact of prevention efforts.
    CDC is committed to achieving the health promotion and disease 
prevention objectives of ``Healthy People 2000,'' a national activity 
to reduce morbidity and mortality and improve the quality of life. This 
announcement is related to the priority areas of Alcohol and Other 
Drugs, Environmental Health, Maternal and Infant Health, and 
Surveillance and Data Systems. (To order a copy of ``Healthy People 
2000,'' see section WHERE TO OBTAIN ADDITIONAL INFORMATION.)

Authority

    This program is authorized under Sections 301 and 317(k)(2) of 
Public Health Service Act (42 U.S.C. 241 and 247b(k)(2), as amended.

Smoke-Free Workplace

    CDC strongly encourages all recipients to provide a smoke-free 
workplace and to promote the non-use of all tobacco products, and 
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in 
certain facilities that receive Federal funds in which education, 
library, day care, health care, and early childhood development 
services are provided to children.

Eligible Applicants

    Eligible applicants are the State health departments or other State 
agencies or departments deemed most appropriate by the State to direct 
and coordinate the State's surveillance activities and that: (1) 
represent a population of not less than 25,000 live births per year 
within

[[Page 28033]]

a State, group of States, or geographically-defined area; and/or (2) 
demonstrate evidence of alcohol problems among women in the targeted 
study population.
    This eligibility includes bona fide agents or instrumentalities of 
States which are acting as the official agent of the State(s) for 
surveillance activities.
    This eligibility also includes the District of Columbia, American 
Samoa, the Commonwealth of Puerto Rico, the Virgin Islands, the 
Federated States of Micronesia, Guam, the Northern Mariana Islands, the 
Republic of Marshall Islands, the Republic of Palau, and federally 
recognized Indian tribal governments.
    State agencies applying under this announcement that are other than 
the official State health department must provide written concurrence 
for the application from the official State health agency.
    Only one application from each single State or group of States may 
enter the review process and be considered for an award under this 
announcement.

    Note: Effective January 1, 1996, Public Law 104-65 states that 
an organization described in section 501(c)(4) of the Internal 
Revenue Code of 1986 which engages in lobbying activities shall not 
be eligible to receive Federal funds constituting an award, grant 
(cooperative agreement), contract, loan, or any other form.

Availability of Funds

    Approximately $300,000 will be available in FY 1997 to award up to 
3 cooperative agreements. Projects are expected to begin on or about 
September 30, 1997, and will be made for a 12-month budget period 
within a project period of up to 5 years. Funding estimates may vary 
and are subject to change.
    Continuation awards within the approved project period will be made 
on the basis of satisfactory progress and the availability of funds.

Use of Funds Restrictions on Lobbying

    Applicants should be aware of restrictions on the use of HHS funds 
for lobbying of Federal or State legislative bodies. Under the 
provisions of 31 U.S.C. Section 1352 (which has been in effect since 
December 23, 1989), recipients (and their subtier contractors) are 
prohibited from using appropriated Federal funds (other than profits 
from a Federal contract) for lobbying Congress or any Federal agency in 
connection with the award of a particular contract, grant, cooperative 
agreement, or loan. This includes grants/cooperative agreements that, 
in whole or in part, involve conferences for which Federal funds cannot 
be used directly or indirectly to encourage participants to lobby or to 
instruct participants on how to lobby.
    In addition, the FY 1997 HHS Appropriations Act, which became 
effective October 1, 1996, expressly prohibits the use of 1997 
appropriated funds for indirect or ``grass roots'' lobbying efforts 
that are designed to support or defeat legislation pending before State 
legislatures. This new law, Section 503 of Pub. L. No. 104-208, 
provides as follows:

    Sec. 503(a) No part of any appropriation contained in this Act 
shall be used, other than for normal and recognized executive-
legislative relationships, for publicity or propaganda purposes, for 
the preparation, distribution, or use of any kit, pamphlet, booklet, 
publication, radio, television, or video presentation designed to 
support or defeat legislation pending before the Congress, * * * 
except in presentation to the Congress or any State legislative body 
itself.
    (b) No part of any appropriation contained in this Act shall be 
used to pay the salary or expenses of any grant or contract 
recipient, or agent acting for such recipient, related to any 
activity designed to influence legislation or appropriations pending 
before the Congress or any State legislature.
    Department of Labor, Health and Human Services, and Education, and 
Related Agencies Appropriations Act, 1997, as enacted by the Omnibus 
Consolidated Appropriations Act, 1997, Division A, Title I, Section 
101(e), Pub. L. No. 104-208 (September 30, 1996).

Background

    Birth defects are the leading cause of infant mortality in the 
United States, accounting for more than 20 percent of all infant 
deaths. In addition, birth defects are the fifth leading cause of years 
of potential life lost and contribute substantially to childhood 
morbidity and long-term disability. Fetal Alcohol Syndrome is a leading 
birth defect that causes significant lifetime disability. Unlike many 
other birth defects, however, FAS has a known etiology and is 
preventable. The success of any public health prevention or 
intervention program must be measured by comparing the incidence or 
prevalence of a condition before and after implementation of programs. 
Incidence and prevalence data are also important for estimating the 
societal impact of a disorder and planning for resource use.
    The specific Healthy People 2000 health objective is to reduce the 
rate of FAS in the general population to no more than .12 cases per 
1,000 live births by the year 2000. The original baseline data for this 
objective (.22 per 1,000 live births in 1987) were derived from a 
national hospital-based epidemiologic surveillance program of birth 
defects--the Birth Defects Monitoring Program (BDMP) of CDC. Although 
more recent rates of .67 per 1,000 have been generated by this system, 
this increase probably represents improvements in the recognition and 
reporting of FAS at birth. Other studies using different methods and 
data sources report prevalence rates ranging from .33 to 2.2 per 1000.
    Developing a surveillance system for FAS presents unique challenges 
that cannot be met by current birth defects monitoring systems that 
focus only on the first year of life. There is no simple, objective 
laboratory test for the diagnosis of FAS. The diagnosis is based 
primarily on clinical examination and the application of diagnostic 
criteria in each of three categories: (1) prenatal or postnatal growth 
retardation; (2) central nervous system abnormalities which may 
manifest as developmental delays in childhood; and (3) characteristic 
abnormal facial features (including short palpebral fissures, a long 
smooth philtrum, thin upper lip, and flattened midfacial area). Since 
no single characteristic (beyond the facial dysmorphia) is specific to 
the diagnosis of FAS, the application of these criteria requires 
expertise in recognizing dysmorphic features and differentiating this 
condition from other syndromes and malformations.
    Furthermore, some of the cardinal facial features and central 
nervous system abnormalities are not apparent during the first year of 
life. FAS, like other syndromes, becomes easier to diagnose with 
increasing age, at least until about puberty.
    Clearly, surveillance of FAS cannot depend on any single source for 
case ascertainment. A multiple source method which may include, but is 
not limited to, birth defects monitoring programs, developmental 
disabilities or special needs registries, hospital discharge data, 
special education and other school records, Medicaid data, vital 
statistics, private provider and special diagnostic units, screening 
and case-finding activities in special settings, and other population-
based systems appear promising. The theoretical basis for this 
multiple-source approach is that children with FAS, because of the 
nature of the health and developmental problems associated with the 
condition, are likely to encounter one or more of these resources for 
services at some point in early childhood or school age. Often-times, 
however, the correct diagnosis is not made. Thus, an integral component 
of a multiple-source methodology is provider education and training.

[[Page 28034]]

Purpose

    The purpose of this cooperative agreement is to:
    A. Enhance an existing system or to develop and implement a new 
system which uses a multiple source surveillance methodology to enable 
researchers to determine the prevalence of FAS within a geographically-
defined area (statewide, multiple States, or regions of a State);
    B. Improve the capacity to ascertain true cases of FAS and generate 
population-based surveillance data;
    C. Establish relationships with facilities or programs where 
children with FAS are likely to be diagnosed or receive services, such 
as high-risk newborn registries, special diagnostic units, special 
education programs, special needs registries, and other programs or 
settings for children with developmental disabilities;
    D. Evaluate the completeness of the surveillance system 
methodology, the system's ability to generate a prevalence rate for 
FAS, and the potential for monitoring trends;
    E. Implement provider training and education on FAS to improve case 
ascertainment, referral and case management practices, and prevention 
activities.

Program Requirements

    In conducting activities to achieve the purpose of this cooperative 
agreement, the recipient will be responsible for the activities under 
A. (Recipient Activities) below, and CDC will be responsible for 
activities under B. (CDC Activities) below:

A. Recipient Activities

    1. Meet at CDC to:
    a. Develop and agree on a surveillance case definition.
    b. Develop and agree on a plan to implement the data collection 
instruments and methods for abstracting medical and school records as 
appropriate.
    c. Develop an evaluation plan for the surveillance system. This 
will include a plan for estimating false positive and false negative 
error rates, such as a comparison of cases identified using the 
surveillance criteria with more comprehensive clinical criteria or 
follow-up of cases to confirm the diagnosis.
    d. Develop a plan for publishing prevalence rates and rates among 
various risk groups and authorship on other publications emanating from 
the surveillance activities.
    2. Develop and implement a multiple source methodology to ascertain 
cases of FAS and generate population-based estimates of the prevalence 
of FAS.
    3. Develop a plan for provider education and training on FAS case 
ascertainment.
    4. Establish collaborative relationships (for the purpose of 
diagnosis and case ascertainment) with appropriate diagnostic units 
serving the surveillance population, such as special genetics, 
dysmorphology, neurobehavioral, and developmental pediatrics clinics.
    5. Establish collaborative relationships with agencies providing 
services to children with FAS including special education, foster care 
programs, high-risk newborn nurseries, and other high-risk service 
environments.
    6. Implement quality assurance procedures to ensure that study 
protocols are being followed, and that the surveillance procedures are 
being uniformly implemented in the study sites.
    7. Collaborate with other participating sites on a manuscript which 
describes the surveillance system, case definitions, methodology, 
collaborative relationships, data collection, findings (including the 
prevalence rate of FAS), and recommendations across sites.

B. CDC Activities

    1. Convene two meetings of awardees in the first nine months, then 
annually thereafter, to develop and review the surveillance case 
definition, design surveillance data collection instruments, and 
develop study protocols and procedures.
    2. Provide leadership and current scientific information on 
relevant health information and surveillance approaches, and provide 
oversight of the surveillance and research design to ensure adherence 
to appropriate standards.
    3. Provide guidance and technical assistance in the development of 
an evaluation plan for the surveillance system.
    4. Conduct periodic site visits to observe and discuss development 
and implementation of activities and analysis of surveillance data.
    5. Provide guidance and coordinate the aggregation and analysis of 
data across surveillance sites.
    6. Maintain multi-state data base to develop FAS prevalence rates 
and other information for reports and other publications, when 
appropriate.
    7. Cooperate in preparation and publication of study results.

Technical Reporting Requirements

    An original and two copies of semiannual progress reports are 
required of all awardees. Time lines for the semiannual reports will be 
established at the time of award. An original and 2 copies of the 
Financial Status Report (FSR) are required no later than 90 days after 
the end of the budget period. A final program report and FSR are due no 
later than 90 days after the end of the project period. All reports are 
submitted to the Grants Management Branch, Procurement and Grants 
Office, CDC.

Application Content

    Applications must be developed in accordance with PHS Form 5161-1 
(Revised 7/92, OMB Number 0937-0189). All material must be typewritten, 
double-spaced pages, with type no smaller than 10 CPI (12 point), on 
8.5''  x  11'' paper, with at least 1'' margins, headings, and footers, 
unbound and printed on one side only. Number each page clearly, and 
provide a complete index to the application and appendices. Do not 
include any spiral or bound materials or pamphlets. All graphics, maps, 
overlays, etc., should be in black and white and meet the above 
criteria.
    The applicant should provide a detailed description of first-year 
activities and briefly describe future-year objectives and activities. 
Do not include a detailed budget or detailed budget justification as 
part of the Program Narrative.

A. Abstract

    A one-page, single-spaced, typed abstract must be submitted with 
the application. The heading should include the title of the grant 
program, project title, organization, name and address, project 
director and telephone number. The abstract should briefly summarize 
the program for which funds are requested, the activities to be 
undertaken, and the applicant's organization and composition. The 
abstract should precede the Program Narrative. The abstract should 
include the required cohort statistics and eligibility status.

B. Program Narrative (not to exceed 25 pages)

    The Program Narrative should specifically address all items in the 
``PROGRAM REQUIREMENTS.'' All items of the Program Narrative should 
begin on a new page. If the proposed program is a multiple-year 
project, the applicant should provide detailed description of the 
first-year activities, and briefly describe future-year objectives and 
activities. The ``EVALUATION CRITERIA'' will serve as the basis for 
evaluating the

[[Page 28035]]

application; therefore, the narrative of the application should address 
the following:
1. Applicant's Understanding of the Problem
    The applicant should demonstrate an understanding of FAS, the 
challenges to conducting surveillance of FAS and other conditions 
associated with prenatal alcohol use, and an understanding of the 
applicant's abilities and resources to conduct FAS surveillance.
2. Applicant's Description of the Surveillance Methodology
    The applicant's description should include at least the following:
    a. A proposed surveillance case definition and how the definition 
will be operationalized given the described methodology;
    b. Clearly described methods for case ascertainment using multiple 
sources. Methods should include a plan for estimating the completeness 
of the surveillance system including a plan for estimating sensitivity 
and specificity;
    c. Demonstration of a minimum annual birth population of not less 
than 25,000 in the State or region to be included in the study and/or 
evidence of unusually high rates of alcohol use among women in the 
population (e.g., analysis of BRFSS, PRAMS, or other local surveys) 
from which the surveillance data will be generated;
    d. Methods for collaboration with and written assurances from 
special diagnostic units such as genetics clinics, developmental 
disabilities registries, special education programs, and other agencies 
serving children who may have FAS;
    e. Collaboration with existing state-based birth defects, 
developmental disabilities, or FAS surveillance activities;
    f. A description of the proposed plan for the inclusion of both 
sexes and racial and ethnic minority populations for appropriate 
representation.
3. Project Management and Staffing
    The applicant must demonstrate the ability and expertise to carry 
out population-based surveillance for FAS. The applicant must 
demonstrate the following:
    a. Expertise in abstracting medical and school records;
    b. Expertise in the diagnosis of FAS;
    c. Expertise in epidemiology and public health surveillance;
    d. Plan for personnel resources to be allocated to the project to 
achieve the goals and objectives of the application (dedication of at 
least one full-time professional, scientific employee or equivalent to 
the project is strongly advised).
4. Relationship to Other Funding Sources
    The applicant must describe the availability of State resources and 
other sources of funds to support the surveillance activities in this 
cooperative agreement. The applicant must describe how its program will 
build on existing surveillance, screening, diagnosis, or service-
related activities for FAS.
5. Budget Justification and Adequacy of Facilities
    This section must include a detailed first-year budget narrative 
justification with future annual projections. Budgets should include 
costs for travel for two project staff to attend at least two two-day 
meetings in Atlanta with CDC staff. The applicant should describe the 
program purpose of each budget item. Proposed contracts should identify 
the name of the contractor, if known; describe the services to be 
performed; provide an itemized budget and justification for the 
estimated costs of the contract; specify the period of performance; and 
describe the method of selection.
6. Human Subject Review
    This section must describe how the project will be subject to 
initial and continuing review by the appropriate human subjects 
institutional review committees.

Evaluation Criteria

    Applications will be reviewed and evaluated according to the 
following criteria:

A. Understanding of the Problem (20%)

    The extent to which the applicant has a clear, concise 
understanding of the requirements, objectives, and purpose of the 
cooperative agreement, including the applicant's willingness to 
collaborate and coordinate activities with CDC and other funded sites. 
The extent to which the application reflects an understanding of the 
complexities of FAS surveillance and an understanding of the necessary 
resources to conduct this surveillance.

B. Description of the Surveillance Methodology (50%)

    The extent to which the applicant describes an approach to 
surveillance of FAS that demonstrates collaboration with multiple 
sources (letters of support encouraged) and addresses all issues 
outlined in the ``Program Requirements'' recipient activities section. 
In addition to these program requirements, the extent to which the 
applicant addresses the six issues outlined under section 2 of the 
``Program Narrative'' regarding the surveillance methodology.
    The degree to which the applicant has met the CDC Policy 
requirements regarding the inclusion of women, ethnic, and racial 
groups in the proposed project. This includes:
    (a) The proposed plan for the inclusion of both sexes and racial 
and ethnic minority populations for appropriate representation; (b) The 
proposed justification when representation is limited or absent; (c) A 
statement as to whether the design of the study is adequate to measure 
differences when warranted; and (d) A statement as to whether the plans 
for recruitment and outreach for study participants include the process 
of establishing partnerships with community(ies) and recognition of 
mutual benefits.

C. Project Management and Staffing (30%)

    The extent to which the applicant has the skills, experience, and 
access to data that demonstrate the ability to conduct FAS 
surveillance. The extent to which the applicant addresses the issues 
described in the ``Program Narrative'' section 3. The adequacy of the 
description of the present staff and capability to assemble competent 
and trained staff to conduct FAS surveillance. The applicant shall 
identify all current and potential personnel who will be utilized to 
work on this cooperative agreement, including qualifications and 
specific experience as it relates to the requirements set forth in this 
request.

D. Budget Justification and Adequacy of Facilities (not scored)

    The budget will be evaluated for the extent to which it is 
reasonable, clearly justified, and consistent with the intended use of 
the cooperative agreement funds. The applicant shall describe and 
indicate the availability of facilities and equipment and other sources 
of funds necessary to carry out this project.

E. Human Subject Review (not scored)

    The extent to which the applicant complies with the Department of 
Health and Human Services Regulations (45 CFR Part 46) regarding the 
protection of human subjects.

Funding Preferences

    In making awards, priority consideration may be given to: (1)

[[Page 28036]]

ensuring a racial/ethnic balance; and (2) ensuring rural, urban, and 
national geographic distribution among the grantees.

Executive Order 12372

    Applications are subject to the Intergovernmental Review of Federal 
Programs as governed by Executive Order (E.O.) 12372. E. O. 12372 sets 
up a system for State and local government review of proposed Federal 
assistance applications. Applicants (other than federally recognized 
Indian tribal governments) should contact their State Single Point of 
Contact (SPOC) as early as possible to alert them to the prospective 
applications and receive any necessary instructions on the State 
process. For proposed projects serving more than one State, the 
applicant is advised to contact the SPOC of each affected State or 
tribe. A current list of SPOCs is included in the application kit. If 
SPOCs have any State process recommendations on applications submitted 
to CDC, they should forward them to Ron Van Duyne, Grants Management 
Officer, Grants Management Branch, Procurement and Grants Office, 
Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry 
Road, NE., Room 321, Mailstop E-13, Atlanta, Georgia 30305, no later 
than 60 days after the application deadline date. The granting agency 
does not guarantee to ``accommodate or explain'' State process 
recommendations it receives after that date.
    Indian tribes are strongly encouraged to request tribal government 
review of the proposed application. If tribal governments have any 
tribal process recommendations on applications submitted to CDC, they 
should forward them to Ron Van Duyne, Grants Management Officer, Grants 
Management Branch, Procurement and Grants Office, Centers for Disease 
Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 321, 
Mailstop E-13, Atlanta, Georgia 30305, no later than 60 days after the 
application deadline date. The granting agency does not guarantee to 
``accommodate or explain'' tribal process recommendations it receives 
after that date.

Public Health System Reporting Requirement

    This program is not subject to the Public Health System Reporting 
Requirements.

Catalog of Federal Domestic Assistance Number

    The Catalog of Federal Domestic Assistance Number is 93.283.

Other Requirements

A. Paperwork Reduction Act

    Projects that involve the collection of information from 10 or more 
individuals and funded by this cooperative agreement program will be 
subject to review by the Office of Management and Budget (OMB) under 
the Paperwork Reduction Act.

B. Human Subjects

    If the proposed project involves human subjects, the applicant must 
comply with the Department of Health and Human Services Regulations (45 
CFR Part 46) regarding the protection of human subjects. Assurance must 
be provided to demonstrate that the project will be subject to initial 
and continuing review by an appropriate institutional review committee. 
The applicant will be responsible for providing assurance with the 
appropriate guidelines and form provided in the application kit.
    In addition to other applicable committees, Indian Health Service 
(IHS) institutional review committees also must review the project if 
any component of IHS will be involved or will support the research. If 
any American Indian community is involved, its tribal government must 
also approve that portion of the project applicable to it.

C. Confidentiality

    All personal identifying information obtained in connection with 
the delivery of services provided to any person in any program carried 
out under this cooperative agreement cannot be disclosed unless 
required by a law of a State or political subdivision or unless such a 
person provides written, voluntary informed consent.
    1. Nonpersonal identifying, unlinked information, which preserves 
the individual's anonymity, derived from any such program may be 
disclosed without consent:
    a. In summary, statistical, or other similar form, or
    b. For clinical or research purposes.
    2. Personal identifying information: Recipients of CDC funds who 
must obtain and retain personally identifying information as part of 
their CDC-approved work plan must:
    a. Maintain the physical security of such records and information 
at all times;
    b. Have procedures in place and staff trained to prevent 
unauthorized disclosure of client-identifying information;
    1c. Obtain informed client consent by explaining the risks of 
disclosure and the recipient's policies and procedures for preventing 
unauthorized disclosure;
    d. Provide written assurance to this effect including copies of 
relevant policies; and
    e. Obtain assurances of confidentiality by agencies to which 
referrals are made.
Assurance of compliance with these and other processes to protect the 
confidentiality of information will be required of all recipients. A 
DHHS certificate of confidentiality may be required for some projects.

D. Women, Racial and Ethnic Minorities

    It is the policy of the Centers for Disease Control and Prevention 
(CDC) to ensure that individuals of the various racial and ethnic 
groups will be included in CDC-supported research projects involving 
human subjects, whenever feasible and appropriate. Racial and ethnic 
groups are those defined in OMB Directive No. 15 and include American 
Indian, Alaskan Native, Asian, Pacific Islander, Black and Hispanic. 
Applicants shall ensure that women, racial and ethnic minority 
populations are appropriately represented in applications for research 
involving human subjects. Where a clear and compelling rationale exists 
that inclusion is inappropriate or not feasible, this situation must be 
explained as part of the application. This policy does not apply to 
research studies when the investigator cannot control the race, 
ethnicity, and/or sex of subjects. Further guidance to this policy is 
contained in the Federal Register, Vol. 60, No. 179, pages 47949-47951, 
dated Friday, September 15, 1995.

Application Submission and Deadline

    The original and two copies of the application PHS Form 5161-1 
(Revised 7/92, OMB Number 0937-0189) must be submitted to Joanne 
Wojcik, Grants Management Specialist, Grants Management Branch, 
Procurement and Grants Office, Centers for Disease Control and 
Prevention (CDC), 255 East Paces Ferry Road, NE., Room 321, Mailstop E-
13, Atlanta, Georgia 30305, on or before July 22, 1997.
    1. Deadline: Applications shall be considered as meeting the 
deadline if they are either:
    a. Received on or before the deadline date; or
    b. Sent on or before the deadline date and received in time for 
submission to the special emphasis panel review committee. For proof of 
timely mailing, applicants must request a legibly dated

[[Page 28037]]

U.S. Postal Service postmark or obtain a legibly dated receipt from a 
commercial carrier or the U.S. Postal Service. Private metered 
postmarks will not be acceptable as proof of timely mailing.
    2. Late Applications:
    Applications that do not meet the criteria in 1.a. or 1.b. above 
are considered late. Late applications will not be considered and will 
be returned to the applicant.

Where To Obtain Additional Information

    To receive additional written information call (404) 332-4561. You 
will be asked your name, address, and phone number and will need to 
refer to Announcement 745. A complete program description and 
information on application procedures are contained in the application 
package. Business management technical assistance, and an application 
package may be obtained from Joanne Wojcik, Grants Management 
Specialist, Grants Management Branch, Procurement and Grants Office, 
Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry 
Road, NE., Room 321, Mailstop E-13, Atlanta, Georgia 30305, telephone 
(404) 842-6535; Internet: [email protected].
    FAS surveillance technical assistance may be obtained from Karen 
Hymbaugh at telephone (770) 488-7370, Internet: [email protected], or 
programmatic assistance from Gregg Leeman, at telephone (770) 488-7370, 
Internet: [email protected], Division of Birth Defects and Developmental 
Disabilities, National Center for Environmental Health, Centers for 
Disease Control and Prevention (CDC), 4770 Buford Highway, NE., 
Mailstop F-15, Atlanta, Georgia 30341-3724.
    This and other CDC announcements are available through the CDC 
homepage on the Internet. The address for the CDC homepage is [http://
www.cdc.gov].
    CDC will not send application kits by facsimile or express mail. 
Please refer to Announcement Number 745 when requesting information and 
submitting an application.
    Potential applicants may obtain a copy of ``Healthy People 2000'' 
(Full report; Stock No. 017-001-00474-0) or ``Healthy People 2000'' 
(Summary Report; Stock No. 017-001-00473-1) referenced in the 
``INTRODUCTION'' through the Superintendent of Documents, Government 
Printing Office, Washington, DC 20402-9325, telephone (202) 512-1800.

    Dated: May 16, 1997.
Joseph R. Carter
Acting Associate Director for Management and Operations, Centers for 
Disease Control and Prevention (CDC).
[FR Doc. 97-13429 Filed 5-21-97; 8:45 am]
BILLING CODE 4163-18-P